AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
Neoadjuvant TherapyChemoradiotherapy, AdjuvantChemoradiotherapyEsophagectomyRadiotherapy, AdjuvantRectal NeoplasmsEsophageal NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyTreatment OutcomeSurvival RateNeoplasm StagingDisease-Free SurvivalFluorouracilSurvival AnalysisAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellPrognosisKaplan-Meier EstimateNeoplasm Recurrence, LocalRetrospective StudiesCisplatinRadiotherapy DosageAntineoplastic AgentsHead and Neck NeoplasmsDeoxycytidineBreast NeoplasmsFollow-Up StudiesTaxoidsRadiotherapyCell SurvivalLung NeoplasmsDoxorubicinDrug Administration ScheduleDose FractionationAntimetabolites, AntineoplasticPaclitaxelTumor Markers, BiologicalNasopharyngeal NeoplasmsLymphatic MetastasisCyclophosphamideProportional Hazards ModelsCarboplatinRemission InductionInduction ChemotherapyTime FactorsOrganoplatinum CompoundsCarcinoma, Non-Small-Cell LungSurvivalMultivariate AnalysisEpirubicinLeucovorinNeoplasm MetastasisPositron-Emission TomographyProspective StudiesPreoperative CarePancreatic NeoplasmsRadiotherapy, ConformalAntibodies, Monoclonal, HumanizedFluorodeoxyglucose F18CarcinomaPredictive Value of TestsDisease ProgressionVinblastineCystectomyHypopharyngeal NeoplasmsVincristineImmunohistochemistryLymph Node ExcisionDigestive System Surgical ProceduresEsophagogastric JunctionStomach NeoplasmsBrachytherapyOrgan Sparing TreatmentsNeoplasm, ResidualSalvage TherapyEtoposideAnthracyclinesLaryngeal NeoplasmsReceptor, erbB-2Neoplasm InvasivenessRandomized Controlled Trials as TopicOropharyngeal NeoplasmsMuscle NeoplasmsGastrectomyRecurrenceRadiotherapy, Intensity-ModulatedRadiation InjuriesClinical Trials, Phase II as TopicLiver NeoplasmsBrain NeoplasmsFeasibility StudiesUterine Cervical NeoplasmsNeoplasm GradingTegafurMethotrexateIfosfamideRadiopharmaceuticalsOxonic Acid
RectalDisease-free survivalOutcomesTherapyEsophagectomySquamous cell carcResectionESCCResponse to neoadjuvant chemotherapyNCRTRadiotherapyPrognosisOesophageal cancerPrognosticLocally advanced esophageal cancerPerioperativeGemcitabine-basedCurativeTumorRegimensPostoperativeResectableHazard ratioChemoradiation followedPreoperative chemoradiotherapy2023DefinitiveSurgeryClinicalConcurrentRecurrenceGastric cancerSurgicalTrialsRegressionMetastaticRadiationPlastic StentsLong-term survival
Rectal20
  • Neoadjuvant chemoradiotherapy is recommended to locally advanced rectal cancer, especially for the lower and middle ones. (ac.ir)
  • Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II-III resectable rectal cancer: a meta-analysis of randomized controlled trials. (ac.ir)
  • Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. (ac.ir)
  • Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. (ac.ir)
  • Combined multimodality treatments, including radiation, chemotherapy, and total mesorectal excision have been studied extensively over the past few decades, with efforts toward improving rates of locoregional recurrence and disease-free and overall survival in rectal cancer. (northwestern.edu)
  • Vergo, M, Nimeiri, H & Benson, AB 2009, ' Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer ', Current Colorectal Cancer Reports , vol. 5, no. 3, pp. 151-157. (northwestern.edu)
  • We investigated whether neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer can be restricted to those at high risk of locoregional recurrence (LR) without compromising oncological outcomes. (mdz-aare.ch)
  • Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. (uab.cat)
  • Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. (uab.cat)
  • Conclusion: LODDS appears to be a useful prognostic indicator in the prediction of disease-free survival of patients undergoing neoadjuvant chemoradiotherapy and proctectomy for locally advanced rectal cancer. (uab.cat)
  • Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): initial results of a Phase III Trial. (bjsacademy.com)
  • Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancer. (edcan.org.au)
  • In 2004, a randomized trial from Germany was published establishing a regimen of preoperative chemoradiotherapy and surgery followed by additional cycles of chemotherapy alone as the standard of care for clinical stages T3 or T4, or for node-positive rectal cancer [ 3 ]. (biomedcentral.com)
  • Overall survival (OS) is most affected by the extent of disease, with increasing depth of rectal wall penetration and lymph node involvement being harbingers of worse outcome. (biomedcentral.com)
  • Low BRCA2 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy. (nhri.edu.tw)
  • Some 1194 patients with stage T2 or T3 rectal cancer were randomized to neoadjuvant chemoradiotherapy (standard care) or chemotherapy alone. (bjsacademy.com)
  • Aim: To review the studies published in the last 10 years that relate the baseline, post-neoadjuvant chemoradiotherapy and post-surgery CEA levels with the prognosis of patients with locally advanced rectal cancer. (uc.pt)
  • Studies that comprehended patients diagnosed with rectal cancer stage II and III and submitted to surgery, whether or not preceded by neoadjuvant chemoradiotherapy, were included. (uc.pt)
  • 73.9% of the studies that included the post-neoadjuvant chemoradiotherapy CEA levels indicated its value as a prognostic factor in rectal cancer. (uc.pt)
  • Conclusion: CEA seems to be an important prognostic and predictive factor of response to therapy in rectal cancer, standig out the post-neoadjuvant chemoradioterapy CEA levels. (uc.pt)
Disease-free survival16
Outcomes6
  • Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. (nih.gov)
  • We performed Kaplan-Meier univariate analysis and Cox regression multivariate analysis models to estimate the potential prognostic factors of long-term survival outcomes. (ac.ir)
  • Van der Wilk said those strong outcomes create some uncertainty as to whether all patients need standard surgery after chemoradiotherapy. (medscape.com)
  • Multiple studies have evaluated the outcomes of neoadjuvant chemoradiation followed by surgical resection with surgical resection alone (Table 1) . (appliedradiationoncology.com)
  • Adjuvant modified FOLFIRINOX (fluorouracil, leucovorin, irinotecan and oxaliplatin) and gemcitabine plus capecitabine are the preferred chemotherapy regimens as adjuvant chemotherapy for patients with resected PDAC based on their improved survival outcomes compared to gemcitabine monotherapy in phase 3 trials [ 5 - 7 ]. (e-crt.org)
  • Variables such as demographics, clinical outcomes, and survival were analyzed. (unav.edu)
Therapy22
  • Predictive and prognostic markers to adjuvant systemic chemotherapy have been identified, with the goal of tailoring therapy and continuing improvement in survival. (northwestern.edu)
  • Perioperative therapy is common practice, with chemoradiotherapy after surgery showing a clear survival benefit. (medscape.com)
  • The findings support the avoidance of nCRT in low-risk patients and suggest that in high-risk patients, neoadjuvant therapy should be intensified to improve prognosis. (mdz-aare.ch)
  • Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. (springer.com)
  • A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. (springer.com)
  • Likewise, centralization and application of national guidelines, widespread use of neoadjuvant therapy, and the stage migration phenomenon are serious concerns to be discussed. (frontiersin.org)
  • Initial studies comparing surgery to radiation therapy (RT) showed high operative mortality in surgical patients, and poor survival in both the surgical and radiation-alone patients. (appliedradiationoncology.com)
  • In this review, we examine the role of trimodality therapy in the management of locally advanced esophageal cancer, focusing on controversies surrounding the optimal total neoadjuvant RT dose employed. (appliedradiationoncology.com)
  • BACKGROUND: The role of adjuvant therapy in patients with oesophagogastric adenocarcinoma treated by neoadjuvant chemotherapy is contentious. (ljmu.ac.uk)
  • The aim of this study was to assess the survival benefit of adjuvant therapy in patients with positive (R1) resection margins. (ljmu.ac.uk)
  • CONCLUSION: Adjuvant therapy may improve overall survival and recurrence-free survival after margin-positive resection. (ljmu.ac.uk)
  • Subsequent investigation examined the role of neoadjuvant therapy, and most recently comparisons of these techniques have been published. (biomedcentral.com)
  • Perioperative adaptive dynamic therapy can improve overall survival in patients with localized pancreatic cancer, new research suggests. (medicalbag.com)
  • In this study, we quantified Fusobacterium nucleatum in untreated and post-neoadjuvant chemoradiotherapy (nCRT) samples from LARC patients and investigated its association with therapy response and survival. (gencat.cat)
  • Currently neoadjuvant therapy seems to have a role in managing marginally resectable tumors and tumors with known lymph node involvement. (stomachguide.net)
  • The survival advantage associated with the addition of surgical therapy in esophageal squamous cell carcinoma (ESCC) patients who demonstrate a complete clinical response to chemoradiotherapy is unclear, and many institutions have adopted an organ-preserving strategy of selective surgery in this population. (shengsci.com)
  • We sought to characterize our institutional experience of salvage esophagectomy (for failure of definitive bimodality therapy) and planned esophagectomy (as a component of trimodality therapy) by retrospectively analyzing patients with ESCC of the thoracic esophagus and GEJ who underwent esophagectomy following chemoradiotherapy between 2004 and 2016. (shengsci.com)
  • This number stands to grow following the recent publication of data demonstrating a survival benefit, which will likely prompt more centers to adopt neoadjuvant therapy as a standard of preoperative care (4). (chk1inhibitor.com)
  • concern no longer has merit and the door has opened to more common use of SEMS during neoadjuvant therapy. (chk1inhibitor.com)
  • Metal stents may also reduce the need for unplanned stent exchange in those patients who fail neoadjuvant therapy and need continued palliation until end of life. (chk1inhibitor.com)
  • showed stent malfunction in only 15% of patients who were treated with neoadjuvant therapy (6). (chk1inhibitor.com)
  • All of the patients underwent gemcitabine-based neoadjuvant therapy and 71% of the patients eventually underwent surgery. (chk1inhibitor.com)
Esophagectomy6
  • Background: The globally dominant treatment with curative intent for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy (nCRT) with subsequent esophagectomy. (lu.se)
  • This trial aims to demonstrate that dCRT, with selectively performed salvage esophagectomy only when needed to achieve locoregional tumor control, is non-inferior regarding overall survival, and superior regarding health-related quality of life (HRQOL), compared to nCRT followed by mandatory surgery, in patients with operable, locally advanced ESCC. (lu.se)
  • Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. (medscape.com)
  • The benefits of neoadjuvant chemoradiation (NCRT) compared to upfront esophagectomy (UE) in esophageal squamous cell carcinoma (ESCC) is controversial. (springer.com)
  • A propensity-matched analysis comparing survival after esophagectomy followed by adjuvant chemoradiation to surgery alone for esophageal squamous cell carcinoma. (springer.com)
  • In summary, esophagectomy following chemoradiotherapy for ESCC at our institution has been associated with frequent postoperative morbidity and considerable rates of mortality in both planned and salvage settings. (shengsci.com)
Squamous cell carc4
Resection11
  • more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). (nih.gov)
  • Secondary endpoints include progression-free survival, quality of life, resection rate, and R0 resection rate. (nih.gov)
  • Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy. (bvsalud.org)
  • Rami Manochakian, MD , of Mayo Clinic Florida, offers his perspective on the new phase III findings on osimertinib, a third-generation, central nervous system EGFR tyrosine kinase inhibitor, which demonstrated an unprecedented overall survival benefit for patients with EGFR -mutated, stage IB-IIIA non-small cell lung cancer (NSCLC) after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3). (ascopost.com)
  • Complete surgical resection offers potential for long-term survival. (medscape.com)
  • Two randomized trials have compared the use of definitive CRT to neoadjuvant CRT followed by surgical resection. (appliedradiationoncology.com)
  • IASLC data mining has suggested that patients with one zone of positive N2 nodes (stage III) have post-resection survival equal to people with multiple zones of N1-positive disease (stage II). (pulmccm.org)
  • 1. Intraoperative assessment of the curative potential to predict survival after gastric cancer resection: A national cohort study. (cancercentrum.se)
  • 7. Survival trends of patients with non-metastatic gastric adenocarcinoma in the US and European countries: the impact of decreasing resection rates. (cancercentrum.se)
  • 8. Effect of sex on survival after resection of oesophageal cancer: nationwide cohort study. (cancercentrum.se)
  • Survival following synchronous colon cancer resection. (msdmanuals.com)
ESCC3
  • After matching, patients who underwent UE for clinical stage II ESCC had median survival/3-year overall survival (OS) rates of 27.8 months/39.2% compared with 32.7 months/49.8% in the NCRT group ( p = 0.508). (springer.com)
  • Our data suggest that NCRT strategy improved survival compared with UE in clinical stage III ESCC but not in clinical stage II tumors. (springer.com)
  • Recent advances in neoadjuvant or adjuvant chemotherapy/chemoradiotherapy for treatment of ESCC have significantly improved prognosis. (hku.hk)
Response to neoadjuvant chemotherapy1
  • A Machine Learning Model for Predicting a Major Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer. (cdc.gov)
NCRT1
  • Observational studies indicate that curatively intended chemoradiotherapy, so-called definitive chemoradiotherapy (dCRT) followed by surveillance of the primary tumor site and regional lymph node stations and surgery only when needed to ensure local tumor control, may lead to similar survival as nCRT with surgery, but with considerably less impairment of quality of life. (lu.se)
Radiotherapy6
  • Patients receive 8 cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3 cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36 Gy in 15 fractions) during the second cycle, followed by surgery and 4 cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. (nih.gov)
  • Radiotherapy dose led to a substantial prolongation of survival in patients with locally advanced rectosigmoid junction cancer: a large population based study. (ac.ir)
  • Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity/trunk soft-tissue sarcoma? (psu.edu)
  • This study examines the impact of integrating chemotherapy with neoadjuvant radiotherapy (RT) on overall survival (OS) for patients with high-risk ET-STS. (psu.edu)
  • This study explored whether a radiotherapy booster was beneficial in 148 patients with a complete response to neoadjuvant chemoradiotherapy. (bjsacademy.com)
  • In this study that included 589 procedures, neoadjuvant chemotherapy with radiotherapy had similar effect on complete pathological response and downstaging. (bjsacademy.com)
Prognosis2
  • There is little data on the correlation between the reduction in fluorodeoxyglucose positron emission tomography (FDG- PET ) radioactive accumulation and carbohydrate antigen 19-9 (CA19-9) levels with pathological tumor responses (PTRs) and prognosis after neoadjuvant chemoradiotherapy (NACRT) for patients with pancreatic ductal adenocarcinoma (PDAC). (bvsalud.org)
  • Purpose: Cancer patients receiving various anti-cancer treatments commonly experience malnutrition, and many studies have reported that nutritional status is associated with survival and prognosis. (kjco.org)
Oesophageal cancer2
  • Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. (springer.com)
  • Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer. (cdc.gov)
Prognostic2
  • Response to neoadjuvant chemoradiotherapy and histological type of tumor were the two prognostic factors. (ac.ir)
  • Results High intraepithelial infiltration with CD4 or CD8 T cells was associated with longer overall and recurrence-free survival and formed an independent prognostic factor, outperforming molecular subtype and stage of the disease. (bmj.com)
Locally advanced esophageal cancer3
  • MADRID - More than one third of patients with locally advanced esophageal cancer who have a complete clinical response to neoadjuvant chemoradiotherapy may be able to safely avoid major surgery, findings from the Dutch SANO-trial suggest. (medscape.com)
  • Neoadjuvant treatment for locally advanced esophageal cancer is the standard of care [ 1 , 2 ]. (hindawi.com)
  • This is a review of morbidity and mortality for first 51 MIE procedures for locally advanced esophageal cancer, that were resectable, on post neoadjuvant computerized tomography (CT) of chest and abdomen. (hindawi.com)
Perioperative3
  • A study by Fogh et al of induction chemoradiotherapy followed by surgery, a strategy that is widely used in treating esophageal cancer, found that perioperative morbidity and mortality with this approach was not significantly different in patients aged 70 years or older compared with younger patients. (medscape.com)
  • Perioperative, neoadjuvant chemotherapy or chemoradiotherapy followed by surgery is appropriate. (medscape.com)
  • Unpublished data from a trial in London, the MRC Adjuvant Gastric Infusional Chemotherapy Trial , presented at the American Society of Clinical Oncology this year, did show a statistically significant advantage in perioperative chemotherapy versus surgery alone in resectability, progression-free survival and overall survival for lower esophageal cancer. (stomachguide.net)
Gemcitabine-based1
  • The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients. (nih.gov)
Curative2
  • The benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. (e-crt.org)
  • This retrospective study included 218 patients with localized non-metastatic PDAC who received neoadjuvant FOLFIRINOX and underwent curative-intent surgery (R0 or R1) between January 2017 and December 2020. (e-crt.org)
Tumor2
  • The potential pitfalls of an active surveillance approach is that patients may develop unresectable tumor regrowths, "possibly resulting in inferior overall survival. (medscape.com)
  • The mucinous variety can be visualized via magnetic resonance imaging (MRI) defined by greater than 50% mucin in the tumor, and this variety has recently been shown to respond less favorably to neoadjuvant chemoradiation. (biomedcentral.com)
Regimens2
  • Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. (nih.gov)
  • The PREOPANC-2 trial directly compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer. (nih.gov)
Postoperative1
  • Machine Learning Model for Predicting Postoperative Survival of Patients with Colorectal Cancer. (cdc.gov)
Resectable3
  • Our study will provide evidence on the neoadjuvant treatment of choice for patients with resectable and borderline resectable pancreatic cancer. (nih.gov)
  • Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. (edcan.org.au)
  • Recently, neoadjuvant chemotherapy has been widely used for the management of patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) [ 8 - 13 ]. (e-crt.org)
Hazard ratio1
  • For patient with stage 1B to 3A, the hazard ratio was also 0.49 with a median survival also not reached. (ascopost.com)
Chemoradiation followed1
  • He was treated with neoadjuvant chemoradiation followed by surgery, and he has been in remission for over 5 years. (biomedcentral.com)
Preoperative chemoradiotherapy1
20232
  • Overall, patients who underwent active surveillance had "noninferior overall survival at 2 years," said Berend J. Van der Wilk, PhD candidate, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands, who presented the findings at the European Society for Medical Oncology (ESMO) Annual Meeting 2023 on October 20. (medscape.com)
  • Our results presented at WCLC 2023 build on our legacy of transforming survival expectations with immunotherapy combinations. (advfn.com)
Definitive1
Surgery10
  • Delays in surgery for esophageal cancer did not appear to have much impact on patients' relative survival for early-stage cancer compared with patients who had surgery early, but they did reduce the relative survival rate by almost half for patients with more advanced disease, according to an. (ascopost.com)
  • More than 300 patients who achieved a complete clinical response 12 weeks after completing chemoradiotherapy were randomly assigned to undergo standard surgery or active surveillance. (medscape.com)
  • Overall survival in the active surveillance group was noninferior to that in the standard surgery group at 2 years. (medscape.com)
  • Methods: The National Cancer Data Base was queried for adult patients with high-risk ET-STS who received neoadjuvant RT and limb salvage surgery between 2006 and 2014. (psu.edu)
  • Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. (springer.com)
  • Due to its rarity, no standardized guidelines have been proposed to treat esophageal neuroendocrine carcinoma, although general recommendations suggest surgery with adjuvant chemoradiotherapy as the treatment of choice. (biomedcentral.com)
  • 5 At a median follow-up of 6 years, overall survival was equivalent between the arms, with improvements in local progression-free survival in the surgery group (p = 0.003), but at the cost of a 9% higher risk of treatment-related mortality (p = 0.03). (appliedradiationoncology.com)
  • 9 Similarly, the European Organization for Research and Treatment of Cancer (EORTC) trial 8 randomized SCC patients to surgery alone or neoadjuvant CRT consisting of two 1-week courses of RT, separated by a 2-week break, to a total dose of 37 Gy in 10 fractions with concurrent cisplatin. (appliedradiationoncology.com)
  • Among PDAC patients who underwent surgery following neoadjuvant FOLFIRINOX, adjuvant chemotherapy may be associated with improved survival. (e-crt.org)
  • The meta-analysis included 26 randomized clinical trials designed to compare at least 2 of these treatment strategies: surgery, chemotherapy followed by surgery, and chemoradiotherapy followed by surgery. (gastroenterologyadvisor.com)
Clinical3
  • In the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Shen et al found that the anti-PD-1 antibody tislelizumab significantly improved overall survival vs chemotherapy in the second-line treatment of patients with advanced or metastatic esophageal squamous cell. (ascopost.com)
  • CRT did not provide survival benefits over radiation alone in patients ineligible for clinical trials, suggesting the need to develop less-toxic CRT. (biomedcentral.com)
  • With these six-year results, we are seeing remarkably sustained and durable clinical survival benefits with nivolumab plus ipilimumab year-over-year," said Solange Peters, M.D., Ph.D., professor and chair of medical oncology and the thoracic malignancies program in the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. (advfn.com)
Concurrent2
  • 2 In the 1990s, improvements in survival were made with the addition of concurrent chemotherapy to RT, 3,4 with no patients alive at 3 years in the RT-alone arm. (appliedradiationoncology.com)
  • Recent Findings: Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3-IIB cervical cancer. (elsevierpure.com)
Recurrence2
  • Adjusted Cox regression analyses were used to compare overall and recurrence-free survival according to adjuvant treatment. (ljmu.ac.uk)
  • Although surgical advances including total mesorectal excision continue to decrease rates of local recurrence, the management of locally advanced disease (T3-T4 or N+) benefits from a multimodality approach including neoadjuvant concomitant chemotherapy and radiation. (biomedcentral.com)
Gastric cancer1
Surgical2
  • This multimodal treatment leads to around 60% overall 5-year survival, yet with impaired post-surgical quality of life. (lu.se)
  • Patients with locally advanced disease (patients with T3 or above and/or N1 disease) require neoadjuvant chemoradiotherapy prior to surgical intervention. (hindawi.com)
Trials1
  • There is limited evidence to recommend a specific neoadjuvant chemotherapy regimen because of the lack of prospective comparative trials. (e-crt.org)
Regression1
Metastatic3
  • Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer (mNSCLC), regardless of PD-L1 expression levels. (advfn.com)
  • We are ecstatic to see Opdivo plus Yervoy continue to demonstrate almost double the overall survival rates as chemotherapy after six years of follow-up - the longest-ever for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer. (advfn.com)
  • Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. (nhri.edu.tw)
Radiation2
  • There isn't any difference in native control or survival between high dose rate brachytherapy in contrast with exterior beam radiation [url=https://samoore.com/products/purchase-cytotec-no-rx/] symptoms 8dpiui cytotec 200 mcg online[/url]. (ehd.org)
  • We will additionally review the current and past technologies for radiation treatment delivery, and their impact on overall survival and toxicity in this patient cohort. (appliedradiationoncology.com)
Plastic Stents1
  • of Retrospective comparison studies have shown higher rates of occlusion and complications when plastic stents were used during the neoadjuvant period compared to SEMS (7,8). (chk1inhibitor.com)
Long-term survival1
  • We investigated whether patients with a good response to neoadjuvant chemoradiotherapy will have a relatively better long-term survival compared with those with no response. (ac.ir)